When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Regeneron beats quarterly results on strong demand for ... - AOL

   www.aol.com/news/regeneron-beats-quarterly...

   U.S. sales of Eylea, jointly developed with Bayer AG, rose 2% to $1.53 billion in the reported quarter from a year earlier, above LSEG estimates of $1.47 billion. ... Vabysmo, and raised its full ...

3. Should You Buy the Dip on This Top Growth Stock? - AOL

   www.aol.com/buy-dip-top-growth-stock-103000464.html

   In the second quarter, combined U.S. sales of Eylea and Eylea HD came in at $1.53 billion, an increase of 2% compared to the year-ago period; Eylea's HD revenue accounted for $304 million of that ...

4. Regeneron sees strong initial demand for higher-dose Eylea - AOL

   www.aol.com/news/regeneron-sees-strong-initial...

   Eylea has missed Wall Street sales expectations so far this year, partly due to competition from Roche's Vabysmo since the rival secured U.S. approval last year. Regeneron in a post-earnings call ...

5. Faricimab - Wikipedia

   en.wikipedia.org/wiki/Faricimab

   Faricimab, sold under the brand name Vabysmo (/ v ə ˈ b aɪ z m oʊ / və-BYEZ-mow), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

6. Aflibercept - Wikipedia

   en.wikipedia.org/wiki/Aflibercept

   Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [ 16 ] [ 17 ] It was developed by Regeneron Pharmaceuticals .

7. Regeneron's Eylea could return to growth after nod to high ...

   www.aol.com/news/regenerons-eylea-could-return...

   Shares of Regeneron rose 1.7% to $826.4 in early trading. A longer dosing gap for the drug could help Regeneron take on rival Roche's Vabysmo and also help soften the blow from incoming cheaper ...